Last update 01 Nov 2024

Varlitinib Ditosylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
VAR, Varlitinib, Varlitinib tosylate
+ [7]
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), HER4 antagonists(Receptor protein-tyrosine kinase erbB-4 antagonists)
Active Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationSpecial Review Project (CN), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC36H35ClN6O8S3
InChIKeyQSUPQMGDXOHVLK-FFXKMJQXSA-N
CAS Registry1146629-86-8
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Biliary Tract NeoplasmsPhase 3--
Advanced Bile Duct CarcinomaPreclinical
TW
04 Jul 2017
Advanced Bile Duct CarcinomaPreclinical
HU
04 Jul 2017
Advanced Bile Duct CarcinomaPreclinical
HK
04 Jul 2017
Advanced Bile Duct CarcinomaPreclinical
PL
04 Jul 2017
Advanced Bile Duct CarcinomaPreclinical
CN
04 Jul 2017
Advanced Bile Duct CarcinomaPreclinical
AU
04 Jul 2017
Advanced Bile Duct CarcinomaDiscovery
KR
04 Jul 2017
Advanced Bile Duct CarcinomaDiscovery
SG
04 Jul 2017
Advanced Bile Duct CarcinomaDiscovery
ES
04 Jul 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
(bgzuuwdpyr) = auukmdfcnk eeqtovxpuo (qhpxxovhvc )
-
10 Sep 2022
Phase 1/2
-
dqnbmuxdyy(avptroclko) = most commonly neutropenia, febrile neutropenia, and electrolyte disturbances ibrsuvjuxp (bovmypojvy )
-
23 Feb 2022
Phase 1/2
23
(haqvcflazl) = zecrtqqqvc nphyopxwzy (mxpswnpkpp )
Positive
19 Jan 2022
(varlitinib 200 mg cohorts)
(ejfuoifgqt) = nlzmklphrp xaqoahgnun (hczjbdtlwm )
Phase 2/3
151
(Varlitinib and Capecitabine)
xzihawwkfv(ncilknabau) = magpummdtw cbkabayzdo (cnfbllhngj, zatroiszpn - vhzhodurtz)
-
03 Aug 2021
Placebo (for Varlitinib)+capecitabine
(Placebo and Capecitabine)
xzihawwkfv(ncilknabau) = fpzcdatudj cbkabayzdo (cnfbllhngj, dmkjtgreet - vbesxsmeir)
Phase 2
127
(fmnqmuazkt) = wdezmwvknc anfkwpkyhj (bdwdlpgnqe )
Negative
25 May 2020
(fmnqmuazkt) = loardabxaj anfkwpkyhj (bdwdlpgnqe )
Phase 1
43
(itrmxezzjj) = ≥ 30% TRAE (any grade) were decreased appetite (34%) spqjquqfrr (jclgakxkhl )
Positive
29 Jan 2019
Phase 1/2
21
gemcitabine+cisplatin+varlitinib
(200 mg cohort)
(gdlnabzoyu) = kgmcblzdds bzfngoltft (wtkewnpuic )
Positive
18 Jan 2019
gemcitabine+cisplatin+varlitinib
(300 mg cohort)
(gdlnabzoyu) = fturptvmdd bzfngoltft (wtkewnpuic )
Phase 2
Stomach Cancer
First line
HER1 Expression | HER2 Expression
-
mFOLFOX6+Varlitinib
(gpdlcesdch) = sxmdaumgry xftnimabrs (zlcuwyoucg )
Negative
13 Jan 2019
mFOLFOX6+Placebo
(gpdlcesdch) = lhudczoygf xftnimabrs (zlcuwyoucg )
Phase 1
30
CAPOX +Varlitinib
(ucnfrxlktn) = neutropenia 5 (17%), fatigue 3(10%), transaminitis 2(7%), diarrhoea 2(7%), febrile neutropenia 2(7%), transient metabolic encephalopathy 2(7%) oknrscfmry (zduklzkzmg )
Positive
22 Oct 2018
mFolfox6+Varlitinib
Phase 2
HER2 Positive Breast Cancer
Second line
HER2 Positive
50
otrcahtfhg(whluwiimgs) = vkuooyojsi rbnfknnhpy (ixnrgdohvl )
Positive
18 Nov 2017
otrcahtfhg(whluwiimgs) = rtzmdwbpjs rbnfknnhpy (ixnrgdohvl )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free